VIRal Pulmonary Infections in Older AGE
ConditionViral Pulmonary Infections
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age60+
SponsorGérond'if
About this trial
Severe acute respiratory infections (SARIs) represent one of the leading causes of hospitalization and mortality worldwide. These infections are associated with substantial in-hospital mortality and often constitute a turning point in the medium-term prognosis of older patients and those with comorbid conditions.
SARIs are most frequently of viral origin, involving well-known pathogens such as Orthomyxoviridae (influenza A and B viruses), Pneumoviridae \[(respiratory syncytial virus (RSV), human metapneumovirus (hMPV)\], Paramyxoviridae \[parainfluenza viruses (PIV)\], adenoviruses, or rhinoviruses, as well as emerging viruses such as pandemic influenza strains and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic.
Age-related immune decline (immunosenescence) increases the risk of severe forms and related respiratory or cardiovascular complications. However, the prevalence and burden of the different viral etiologies of Severe acute respiratory infections (SARIs) in older adults remain limited and insufficiently characterized.
The primary objective is to determine the proportion of viral respiratory infections attributable to polymerase chain reaction (PCR)-confirmed pathogen agents among hospitalized older subjects (≥60 years old).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Hospitalized subjects aged ≥ 60 years
A respiratory sample collected and tested by polymerase chain reaction (PCR) during hospitalisation as part of standard of care
Patients with Severe acute respiratory infection (SARI)
Patients with symptoms other than SARI
Disqualifiers
Subjects refusing to participate
Subjects admitted to palliative care unit.
Subjects under guardianship
Any condition that, in the opinion of the investigator, may interfere with the aim of the study or wellbeing of the patient
Trial population
Hospitalized older patients (≥60 years old) tested for PCR as part of standard of care (SoC). Subjects meeting the eligibility criteria will be invited to participate in the study.
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Number of RT-PCR-confirmed positive cases for viral pathogen agents of interest among hospitalized older subjects (≥60 years old)
Time frame
At baselineSecondary outcomes
1
Number of RT-PCR-confirmed positive cases for each viral pathogen agent of interest among hospitalized older subjects
Time frame
From baseline to 3-month follow-up2
Number of RT-PCR-confirmed positive cases for each viral pathogen of interest among hospitalized older subjects according to the vaccination status
Time frame
From baseline to 3-month follow-up3
Number of RT-PCR -confirmed positive cases for each viral respiratory pathogen of interest among hospitalized older subjects according to the indication of PCR
Time frame
From baseline to 3-month follow-up4
Comparison of the prevalence of viral respiratory pathogen of interest among hospitalized older subjects by age groups
Time frame
From baseline to 3-month follow-up Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: